Friday, 16 October 2026European Markets

SARTORIUS STED BIO Stock Impressive Drop 12% So Far On Monday, Underperforms Market

Loading stream...

(vianews) - shares of sartorius sted bio (cac 40: dim.pa) slid by a staggering 12.95% to €240.70 at 14:08 est on monday, after five sequential sessions in a row of gains. cac 40 is sliding 0.5% to €7,351.67, following the last session's upward trend. this seems, at the moment, a somewhat bearish trend exchanging session today.

sartorius sted bio's last close was €276.50, 30.88% under its 52-week high of €400.00.

about sartorius sted bio

sartorius stedim biotech s.a. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. the company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. it also provides cell cultivation, fermentation, separation, purification, and fluid management services; batch and intensified chromatography systems for smaller molecules applications, such as oligonucleotides, peptides, and insulin; and recombinant albumin based solutions. in addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. it serves manufacturers of medications, foods, and chemicals, as well as research and development laboratories. the company was founded in 1870 and is headquartered in aubagne, france. sartorius stedim biotech s.a. is a subsidiary of sartorius ag.

earnings per share

as for profitability, sartorius sted bio has a trailing twelve months eps of €7.8.

pe ratio

sartorius sted bio has a trailing twelve months price to earnings ratio of 30.86. meaning, the purchaser of the share is investing €30.86 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 32.37%.

more news about sartorius sted bio (dim.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com